📰 Nasdaq Pcvx News
Page 3 - Nasdaq Pcvx News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Pcvx. Real-time updates on events, politics, business and more.
December 10, 2023
Mizuho initiated coverage on shares of Vaxcyte (NASDAQ:PCVX – Free Report) in a research report report published on Thursday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $69.00 target price on the stock. Several other research firms have also recently commented on PCVX. Cantor Fitzgerald reiterated an overweight rating and set a […]
November 27, 2023
Harvest Investment Services LLC acquired a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 13,810 shares of the company’s stock, valued at approximately $690,000. A number of other hedge funds […]
November 22, 2023
E Fund Management Co. Ltd. trimmed its stake in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 13.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,834 shares of the company’s stock after selling 1,378 shares during the period. E Fund Management Co. Ltd.’s […]
November 12, 2023
Chicago Partners Investment Group LLC trimmed its position in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 14.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,157 shares of the company’s stock after selling 1,002 shares during the period. Chicago Partners […]
November 11, 2023
Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) – Equities research analysts at Cantor Fitzgerald reduced their FY2023 earnings estimates for Vaxcyte in a research note issued on Tuesday, November 7th. Cantor Fitzgerald analyst L. Chen now expects that the company will earn ($3.33) per share for the year, down from their previous estimate of ($3.05). Cantor […]
November 9, 2023
Vaxcyte (NASDAQ:PCVX – Get Free Report) issued its earnings results on Monday. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.07), Briefing.com reports. Vaxcyte Stock Up 0.7 % Shares of Vaxcyte stock opened at $50.60 on Thursday. Vaxcyte has a 12-month low of $34.11 and a […]
October 14, 2023
Moody Aldrich Partners LLC purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) during the second quarter, Holdings Channel.com reports. The fund purchased 24,665 shares of the company’s stock, valued at approximately $1,232,000. Other hedge funds and other institutional investors also recently made changes to their positions in the company. ETF […]
October 13, 2023
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) has been given a consensus rating of “Buy” by the six research firms that are presently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have issued ratings on the stock in the […]
September 27, 2023
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $52.45, for a total value of $786,750.00. Following the sale, the chief executive officer now directly owns 400,914 shares in the […]
September 24, 2023
Vaxcyte (NASDAQ:PCVX – Get Free Report) and Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations. Analyst Recommendations This is a breakdown of current ratings […]